食管癌同步放化疗PPT幻灯片.pptVIP

cetuximab?(Erbitux)?西妥昔单抗，Bevacizumab?贝伐单抗， ?celecoxib 塞来考昔 ，gefitinib?吉非替尼 ， Hydroxyurea[FHX]《羟(基)脲》，?Nedaplatin（CDGP）奈达铂， Oxaliplatin奥沙利铂; irinotecan依立替康 ，docetaxel多西他赛， Taxol 紫杉醇,红杉醇 Epirubicin表柔比星,?Cisplatin,?Capecitabine卡培他滨 ， 西安交通大学医学院第二附属医院 SECOND AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XI’AN JIAOTONG UNIVERSITY 以上20多项临床试验，涉及以上的药物 以及3DCRT，分段放疗，后程加速超分割等放疗方法。 * Irinotecan plus Cisplatin Paclitaxel plus Cisplatin Docetaxel plus Cisplatin Docetaxel plus fluoropyrimidine Oxaliplatin plus fluoropyrimidine(5-FU or Capecitabine) 西安交通大学医学院第二附属医院 SECOND AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XI’AN JIAOTONG UNIVERSITY 2B * Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. Induction chemotherapy cisplatin 30 mg/m2 /w , irinotecan 65 mg/m2 /w , during weeks 1 to 5. Radiotherapy weeks 8 to 13 in 1.8-Gy/ d a dose of 50.4 Gy. Cisplatin 30 mg/m2 ,irinotecan (40, 50, 65, and 80 mg/m2) were administered on days 1, 8, 22, and 29 of radiotherapy. RESULTS: with no grade 3 or 4 esophagitis, diarrhea（腹泻）, or stomatitis（口炎）. irinotecan 65 mg/m2 was defined as the recommended phase II dose. J Clin Oncol. 2003 Aug 1;21(15):2926-32. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. 西安交通大学医学院第二附属医院 SECOND AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XI’AN JIAOTONG UNIVERSITY * oxaliplatin, cisplatin, and fluorouracil were administered on Days 1 and 29 of radiotherapy. Radiotherapy was delivered in 1.8 Gy daily fractions to a total dose of 50.4 Gy. The recommended dose was 85 mg/m2 oxaliplatin, 55 mg/m2 cisplatin, 3000 mg/m2 96-h fluorouracil infusion. 西安交通大学医学院第二附属医院 SECOND AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XI’AN JIAOTONG UNIVERSITY Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):91-6. Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion flu